Protein sub-unit vaccine

Acces sibility Controls

Implementing Organization

About

India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine for COVID-19, CORBEVAX, developed by Biological E Limited, is a “recombinant protein sub-unit” vaccine developed from the Receptor Biding Domain (RBD) of the spike protein on the virus’s surface is adjuvanted with CpG 1018 and alum, which helps the body to build the immune response against the virus.

Outcome / Output

Excellent safety profile and the most affordable vaccine that can be produced locally at high capacity suitable for any future pandemics

Source

Source URL

technologies/protein-sub-unit-vaccine

Related Research

View All

Quick Information

Focus Area

Protein subunit Vaccine, COVID Vaccine

Status

completed

Output

No. of Research Paper

Technologies (If Any)

No. of PhD Produced

No. of Patents

Filed : 00

Grant : 00

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Acces sibility Controls

Research Projects